from the website"The Company intends to focus its clinical trial program on the evaluation of the effectiveness of REOLYSIN® as a potential treatment for various cancer indications. As disclosed in recent public presentations, the Company expects to broaden its clinical trial program through its association with the National Cancer Institute and the initiation of additional studies. Future trials are expected to include a systemic administration trial and a recurrent malignant glioblastoma trial in the U.S., and various co-therapy studies in the U.S. and the U.K"
I have to imagine the pps will increase with the initiation of each new trial (not far away by the sounds of it) even with no results reported from glio and U.K.